Input parameters relating to effectiveness and intervention costs.

<p>NB. All costs adjusted to 2003 Australian dollars using Australian health price deflators <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026051#pone.0026051-AIHW1" target="_blank">[35]</a>, consumer price index <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026051#pone.0026051-ABS1" target="_blank">[36]</a> and/or purchasing power parities <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026051#pone.0026051-Organisation1" target="_blank">[58]</a> where relevant.</p>a<p>For triangular distributions the most likely values are given, with the minimum and maximum values in brackets.</p>b<p>The value in brackets is the standard error of the mean in the source data, but is used in the model as the standard deviation of the distribution around the change in the population mean of body weight.</p

Disability weights for prevalent diseases, by sex, at baseline [5].

<p>*Disability weights used differ by age; weighted average at baseline (2003) is presented.</p

Relative risks of disease per 1 unit increase of BMI [4], [30].

<p>NB. Values shown are the mean and 95% confidence intervals.</p

Average health care costs per prevalent or incident case of disease.

a<p>Cost per incident case of disease.</p>b<p>Annual cost per prevalent case of disease.</p>c<p>Annual cost per person.</p><p>NB. Costs are in Australian dollars, adjusted to the year 2003.</p

Cost-effectiveness of sibutramine and orlistat when compared with current practice.

<p>NB. Values for health impacts and costs are means and 95% uncertainty intervals, rounded to two significant figures. Cost-effectiveness ratios are ‘ratios of means’ <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026051#pone.0026051-Stinnett1" target="_blank">[59]</a> with 95% uncertainty ranges and are expressed in Australian dollars per disability-adjusted life year, referenced to the year 2003.</p

Results of univariate sensitivity analysis.

<p>NB. Values for DALYs averted are means, while those for A$/DALY are ratios of means, rounded to two significant figures. Cost-effectiveness ratios are in Australian dollars per disability-adjusted life year, referenced to the year 2003. The ICERs include the costs of participants' time and travel and the health care costs in added years of life.</p><p>*In the column titled ‘Incl. utility for BMI-loss’, the calculations have been made after adding the BMI-related QALYs that were gained to the DALYs averted.</p

Estimates of total incremental costs and effects in the target population^a.

a<p>Intervention scenario compared to reference scenario (95% confidence intervals between brackets).</p>b<p>Discounted with 1.5%.</p>c<p>Discounted with 4%.</p

Incremental effects and incremental costs of the intervention scenario vs. the reference scenario from the health care perspective and the societal perspective.

<p>Incremental effects and incremental costs of the intervention scenario vs. the reference scenario from the health care perspective and the societal perspective.</p

GBD 2010 Mental, Neurological, and Substance Use Disorders, Estimated Disability Weights, and Prevalent Cases.

<p>GBD 2010 Mental, Neurological, and Substance Use Disorders, Estimated Disability Weights, and Prevalent Cases.</p

Absolute DALYs Attributable to Mental, Neurological, and Substance Use Disorders, by Age, 2010.

<p>Absolute DALYs Attributable to Mental, Neurological, and Substance Use Disorders, by Age, 2010.</p